Crossref
Regulatory T cell therapies at a translational crossroads
Frontiers · 03.07.2026
DOI: 10.25453/plabs.32896283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers, erschienen am 03.07.2026. Verfasst von Frontiers Policy Labs.
Abstract (Originalsprache)
Prof Rita Carsetti, International Union of Immunological Societies, Germany, and Prof Michael Schmueck-Henneresse, University Health Network, Canada — Bringing tolerance-restoring Treg therapies to patients worldwide requires regulation, manufacturing, and reimbursement to evolve alongside the science. For a full article, please click here.
Schlagwörter
regulatory T cellsTreg therapytranslational medicineregulatory approvalcell therapy manufacturingreimbursementtolerance inductionautoimmunity
Zitieren
APA
Labs, F. P. (2026). Regulatory T cell therapies at a translational crossroads. Frontiers. https://doi.org/10.25453/plabs.32896283
Vancouver
Labs FP. Regulatory T cell therapies at a translational crossroads. Frontiers. 2026. doi:10.25453/plabs.32896283
BibTeX
@article{Labs2026,
author = {Labs, Frontiers Policy},
title = {Regulatory T cell therapies at a translational crossroads},
journal = {Frontiers},
year = {2026},
doi = {10.25453/plabs.32896283}
}
EUVIMED